Synthesis of Ga-radiopharmaceuticals using both generator-derived and cyclotron-produced Ga as exemplified by [Ga]Ga-PSMA-11 for prostate cancer PET imaging.

[Ga]Ga-PSMA-11, a urea-based peptidomimetic, is a diagnostic radiopharmaceutical for positron emission tomography (PET) imaging that targets the prostate-specific membrane antigen (PSMA). The recent Food and Drug Administration approval of [Ga]Ga-PSMA-11 for PET imaging of patients with prostate cancer, expected follow-up approval of companion radiotherapeutics (e.g.

Synthesis of Ac-PSMA-617 for Preclinical Use.

Background: The recent approval of radiopharmaceuticals for diagnosis and treatment of cancer is ushering nuclear medicine into a new era of theranostics and alpha therapy using radiopharmaceuticals labeled with Ac shows remarkable results in clinical trials. As such, reliable methods for the synthesis and quality control of Ac-radiopharmaceuticals are needed.

Objective: Ac-PSMA-617 is being used for targeted alpha therapy in patients with prostate cancer, and we had cause to synthesize the agent for preclinical use.

Cyclotron-based production of Ga, [Ga]GaCl, and [Ga]Ga-PSMA-11 from a liquid target.

Purpose: To optimize the direct production of Ga on a cyclotron, via the Zn(p,n)Ga reaction using a liquid cyclotron target. We Investigated the yield of cyclotron-produced Ga, extraction of [Ga]GaCl and subsequent [Ga]Ga-PSMA-11 labeling using an automated synthesis module.

Methods: Irradiations of a 1.

High-Yielding Automated Convergent Synthesis of No-Carrier-Added [C-]-Labeled Amino Acids Using the Strecker Reaction.

A new variant of the Strecker synthesis using no-carrier-added [C]cyanide for the synthesis of radiolabeled amino acids is described. The protocol is fully automated using a radiochemistry synthesis module and applied to the production of a number of new PET radiotracers. [C-]sarcosine, [C-]methionine, [C-]--phenylglycine, and [C-]glycine are all synthesized in moderate to good radiochemical yields.

Increased 18F-FDG uptake is predictive of rupture in a novel rat abdominal aortic aneurysm rupture model.

Objective: To determine whether F-fluorodeoxyglucose (F-FDG) micro-positron emission tomography (micro-PET) can predict abdominal aortic aneurysm (AAA) rupture.

Background: An infrarenal AAA model is needed to study inflammatory mechanisms that drive rupture. F-FDG PET can detect vascular inflammation in animal models and patients.

Imaging of carrageenan-induced local inflammation and adjuvant-induced systemic arthritis with [(11)C]PBR28 PET.

Introduction: [(11)C] PBR28 binding to translocator protein (TSPO) was evaluated for imaging of acute and chronic inflammation using two established rat models.

Methods: Acute inflammation was induced by local carrageenan injection into the paw of Fisher 344 rats (model A). T-cell mediated adjuvant arthritis was induced by heat-inactivated Mycobacterium butyricum injection in Lewis rats (model B).

Assessment of the biodistribution of an [(18) F]FDG-loaded perfluorocarbon double emulsion using dynamic micro-PET in rats.

Perfluorocarbon (PFC) double emulsions loaded with a water-soluble, therapeutic agent can be triggered by ultrasound in a process known as acoustic droplet vaporization. Elucidating the stability and biodistribution of these sonosensitive vehicles and encapsulated agents is critical in developing targeted drug delivery strategies using ultrasound. [(18) F]fluorodeoxyglucose (FDG) was encapsulated in a PFC double emulsion and the in vitro diffusion of FDG was assessed using a Franz diffusion cell.

Registration methodology for histological sections and in vivo imaging of human prostate.

Rationale And Objectives: Registration enables quantitative spatial correlation of features from different imaging modalities. Our objective is to register in vivo imaging with histologic sections of the human prostate so that histologic truth can be correlated with in vivo imaging features.

Materials And Methods: In vivo imaging of the prostate included T2-weighted anatomic and diffusion weighted 3-T magnetic resonance imaging (MRI) as well as 11C-choline positron emission tomography (PET).